Spironolactone Causes Truly Elevated (Not Falsely Elevated) Plasma Aldosterone Levels
Yes, spironolactone causes plasma aldosterone levels to rise, but this represents a true physiologic elevation—not a false laboratory artifact—resulting from competitive receptor blockade and impaired aldosterone metabolism. 1, 2
Mechanism of Aldosterone Elevation
Receptor Blockade Leading to Compensatory Increase
Spironolactone competitively binds aldosterone receptors in the distal renal tubule, blocking aldosterone's action and triggering a compensatory feedback response that increases endogenous aldosterone secretion. 1
This represents a true biological elevation of circulating aldosterone, not assay interference or a laboratory false-positive. 1
Metabolic Inhibition of Aldosterone Clearance
Spironolactone and its primary metabolite canrenone directly inhibit UGT2B7-mediated aldosterone glucuronidation in both liver and kidney, reducing aldosterone clearance with inhibitor constants (Ki) of 3–5 μM for spironolactone and 2–4 μM for canrenone. 2
This pharmacokinetic interaction further contributes to elevated plasma aldosterone concentrations during spironolactone therapy. 2
Additional evidence suggests spironolactone may inhibit aldosterone biosynthesis at the 18-hydroxylation and 18-oxidation steps, though this effect is overshadowed by the compensatory increase in secretion. 3
Clinical Implications for Diagnostic Testing
Impact on Primary Aldosteronism Screening
In patients taking spironolactone, plasma renin activity (PRA) escapes suppression and reaches very high levels, while aldosterone remains elevated, making the aldosterone-to-renin ratio (ARR) unreliable for screening primary aldosteronism. 4
Spironolactone must be discontinued for at least 4–6 weeks before accurate ARR testing, as it causes the strongest distortion of the renin-angiotensin-aldosterone axis among antihypertensive medications. 4
Beta-blockers also significantly suppress renin and falsely elevate the ARR, while calcium channel blockers have minimal impact on screening accuracy. 5, 4
Distinguishing True from Artifactual Elevation
The aldosterone elevation on spironolactone is not due to immunoassay cross-reactivity or laboratory interference—it reflects genuine increases in circulating hormone concentrations from both enhanced secretion and reduced clearance. 2, 3
This contrasts with true false-positive laboratory results (e.g., drug interference with immunoassays), which do not occur with spironolactone and aldosterone testing. 5
Common Pitfalls
Do not interpret elevated aldosterone levels during spironolactone therapy as evidence of primary aldosteronism—the drug itself causes this elevation through multiple mechanisms. 3, 4
Attempting to screen for primary aldosteronism while a patient remains on spironolactone will yield uninterpretable results due to marked renin elevation and persistent aldosterone secretion. 4
The elevation persists throughout treatment duration, with significant increases in deoxycorticosterone and corticosterone also observed by days 14–28 of therapy. 3